UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
Go back to UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis| (NYSE: UCB) | Delayed: 34.63 +0.36 (1.05%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.27 | 52 Week High | $ | |||
| Open | $34.50 | 52 Week Low | $ | |||
| Day High | $34.77 | P/E | N/A | |||
| Day Low | $34.47 | EPS | $ | |||
| Volume | 966,414 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 158.72 +0.71 (0.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $158.01 | 52 Week High | $46.25 | |||
| Open | $157.44 | 52 Week Low | $32.74 | |||
| Day High | $160.08 | P/E | N/A | |||
| Day Low | $157.07 | EPS | $0.00 | |||
| Volume | 12,696 | |||||
